Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...
WFXG

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic ...

Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and ...
European Medical Journal

Osteopathic Treatment May Improve Asthma Function

OSTEOPATHIC manipulative treatment (OMT) may improve pulmonary function in asthma, though current evidence remains limited ...
Pulmonology Advisor

Extrafine BDP/FF/G May Improve Outcomes in Symptomatic COPD

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.
The Cardiology Advisor

Death, Major Morbidity Reported in 87 Percent With Single-Ventricle Disease

For children with single-ventricle disease, death or major morbidity occurs in 87%, and shunt type impact varies.
United News of Bangladesh on MSN

Air quality in Dhaka 'moderate' as city ranks 10th globally

Dhaka, March 20 -- Dhaka, the densely populated capital of Bangladesh, ranked 10th among the world's most polluted cities on Friday morning, recording an Air Quality Index (AQI) of 126 at 11:15 am.

Dupixent's Impact On Sanofi: A Quantitative Projection Of Its Revenue

Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...
Healio

COPD exacerbation risk falls with dry powder vs. metered-dose, soft mist inhaler

New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD ...
Mena FN

Results From Phase 3 Study Of Rademikibart In Moderate-To-Severe Atopic Dermatitis To Be Presented In The Late-Breaking Research Session At The 2026 American Academy Of ...

(MENAFN- GlobeNewsWire - Nasdaq) SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage ...
manilatimes

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of ...

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on ...